CERo Therapeutics(US:CERO) Globenewswire·2025-12-02 12:30Core Points - CERo Therapeutics Holdings, Inc. will trade on the OTCQB market under the ticker symbol CERO effective December 2, 2025 [2] - The company is exploring options for an up-list to a major exchange to enhance liquidity and investor accessibility [2] - CERo is focused on advancing its Phase 1 clinical trial of CER-1236 for acute myeloid leukemia (AML), with a significant increase in starting dosage compared to previous cohorts [3] - CERo's proprietary T cell engineering approach integrates innate and adaptive immunity to target tumors more effectively, potentially offering advantages over existing CAR-T therapies [4] - The company has initiated clinical trials for its lead product candidate, CER-1236, aimed at treating hematologic malignancies [4]